Paper Details

  1. Home
  2. Paper Details

Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.

Author: LiuPing, ShenLiangfang, TanXiao, TongJing-Shan, YaoHongliang, ZhangZhongqiang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Retracted PublicationCases where a publication has been formally withdrawn due to the discovery of serious errors or misconduct.

Overview

This study investigates the potential of combining tazemetostat, an EZH2 inhibitor, with 5-FU to enhance its efficacy and reduce adverse effects in colorectal cancer (CRC) treatment. The combination showed synergistic antitumor activity and improved 5-FU sensitivity, suggesting a promising strategy for CRC therapy.
Paper Details　
Original Abstract of the Article :
Although the survival rate of patients with cancer have increased due to the use of current chemotherapeutic agents, adverse effects of cancer therapy remain a concern. The reversal of drug resistance, reduction in harmful side effects and accelerated increase in efficiency have often been addressed...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733595/

データ提供：米国国立医学図書館（NLM）

Inhibition of EZH2: A New Strategy for Enhancing 5-FU Sensitivity in Colorectal Cancer

This study explores the synergistic antitumor effect of combining the histone methyltransferase EZH2 inhibitor tazemetostat (EPZ-6438) with 5-fluorouracil (5-FU) in colorectal cancer (CRC). Imagine a camel caravan facing a fierce predator, with tazemetostat acting as a smart scout who identifies the predator's weakness (EZH2) and 5-FU being the powerful archer who delivers the final blow.

The study found that tazemetostat combined with 5-FU exhibited synergistic antitumor effects both in vitro and in vivo. This means that the combination was more effective than either drug alone. It's like the camel caravan employing both scouts and archers to maximize its chances of survival.

A Novel Combination Therapy for Colorectal Cancer

This research presents a promising new combination therapy for CRC. It's like a camel caravan adapting to its environment by using a combination of strategies to overcome challenges.

Harnessing the Power of Combination Therapies

This study emphasizes the potential of combination therapies in cancer treatment. Just as a camel caravan relies on teamwork and diverse skillsets, we can harness the power of combined therapies to combat complex diseases.

Dr. Camel's Conclusion

This study offers a novel and effective approach to enhancing the therapeutic effect of 5-FU in CRC. It's a reminder that understanding the complexities of cellular pathways can lead to innovative and impactful treatment strategies.

Date :
  1. Date Completed 2021-04-09
  2. Date Revised 2023-04-03
Further Info :

Pubmed ID

33311453

DOI: Digital Object Identifier

PMC7733595

Related Literature

Article Analysis
・Side Effects of tazemetostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.